[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650849":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":18,"responsibleParty":32,"collaborators":18,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":18,"eligibilityCriteria":39,"healthyVolunteers":40,"sex":41,"minAge":42,"maxAge":18,"enrollmentInfo":43,"targetDuration":18,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":18,"overallStatus":52,"whyStopped":18,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":18},{"fullName":5,"class":6},"Changchun BCHT Biotechnology Co.","INDUSTRY",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"live-attenuated zoster vaccine","EXPERIMENTAL",[12],"Biological: live-attenuated zoster vaccine",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"BIOLOGICAL","one dose of live-attenuated zoster vaccine to the particpent only administered one dose of recombinant zoster vaccine",[9],null,[20],{"name":21,"affiliation":22,"role":23},"yan shaohong","Inner Mongolia Autonomous Region Center for Disease Control and Prevention","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Chen Xin","CONTACT","0431-87078295","chenxin@bchtpharm.com",{"name":31,"role":27,"phone":18,"phoneExt":18,"email":18},"tian xiaoling",{"type":33,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100650849","early-phase-1-a-study-on-the-live-attenuated-herpes-zoster-vaccine-for-sequential-booster-immunization-following-recombinant-herpes-zoster-vaccine-100650849",false,"NCT07753265","A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine","Inclusion Criteria:\n\n* Age ≥ 50 years old;\n* The participant can provide personal informed consent and sign the informed consent form;\n* temperature ≤ 37.0℃ on the day of administration;\n* capable of complying with the requirements of the clinical trial protocol to complete the trial.\n\nExclusion Criteria:\n\n* Subjects with immunodeficiency or immunosuppression caused by underlying diseases or treatments, including primary\u002Facquired immunodeficiency (e.g., AIDS and other virus-induced immunodeficiency), hematologic malignancies (leukemia, lymphoma or other bone marrow\u002Flymphoid neoplasms), ongoing immunosuppressive therapy, or radiotherapy\u002Fchemotherapy for malignancies.\n* Subjects with a history of allergic reaction to any component of the investigational product.\n* Subjects with acute infection or acute exacerbation of chronic infection (vaccination should be deferred).\n* Women of non-postmenopausal status with positive pregnancy test, pregnant or lactating women, or those planning pregnancy within 6 months.\n* Subjects with prior history of herpes zoster.\n* Subjects with prior receipt of varicella or herpes zoster vaccine.\n* Receipt of live-attenuated vaccines within 14 days, or subunit\u002Finactivated vaccines within 7 days prior to study vaccination.\n* Receipt of whole-blood, plasma or immunoglobulin within 5 months before, or within 3 weeks after study vaccination.\n* Receipt of investigational drugs from other clinical trials within 1 month before study vaccination, current participation in another clinical trial, or planned use of investigational agents during study period.\n* Current or planned use of salicylates (including aspirin, diflunisal, etc.).\n* Uncontrolled abnormal blood pressure at screening (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg despite medication).\n\nSubjects meeting contraindications or precautions specified in the product's prescribing information.\n\n* Any condition that, in the Investigator's opinion, may interfere with study evaluations.",true,"ALL","50 Years",{"count":44,"type":45},100,"ESTIMATED","INTERVENTIONAL",[48],"EARLY_PHASE1","Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.",[51],"Herpse Zoster","NOT_YET_RECRUITING","2026-08-04",{"date":55,"type":56},"2026-08-07","ACTUAL",{"date":58,"type":45},"2026-08-13",{"date":60,"type":45},"2026-09-20",{"name":5,"class":6}]